For example, a combination of adagrasib with cetuximab led to a 40% objective response rate (ORR), while sotorasib plus panitumumab produced a 30% ORR in chemotherapy-refractory KRAS G12C-mutant CRC patients [151,152]. This evidence concerns the gene KRAS and colorectal carcinoma.